Elizabeth Rau, MD
Interventional Cardiology · Coeur D Alene, IDNPI 1538455878
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $503 of the $671 with a category attached, or 75.0%. 10 manufacturers reported payments, led by Abbott at 36.6% of the total. Reporting peaked in 2019 at $381 and has fallen 72.0% since, to $106 in 2025. That places this record below the midpoint for interventional cardiology clinicians in ID, where the typical reported total is $3,406.
Across 16 payments — averaging $41.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$246
- Philips North America LLC$168
- Medtronic$57
- Johnson & Johnson$38
- Novartis$36
- BD$30
- plus $96 from 4 others
What the payments were for
- Travel & lodging$16825%
- Food & beverage$50375%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 3 | $246 |
| Philips North America LLC | 3 | $168 |
| Medtronic | 1 | $57 |
| Johnson & Johnson | 2 | $38 |
| Novartis | 2 | $36 |
| BD | 1 | $30 |
| Boston Scientific | 1 | $29 |
| AstraZeneca | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Gilead | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$671 in reported general payments places this provider in the 10th percentile of 29 interventional cardiology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $36,300 |
| Atorvastatin Calcium | 28 | $1,084 |
| Potassium Chloride | 16 | $539 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 26 | $442 |
| ClopidogrelClopidogrel Bisulfate | 23 | $294 |
| Metoprolol Succinate | 22 | $137 |
| Amlodipine Besylate | 21 | $126 |
| Nitroglycerin | 18 | $103 |
| Furosemide | 24 | $91 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Coeur D Alene
- Eric WallaceCoeur D Alene$4K
- Charles CuiCoeur D Alene$3K
- Mark TroianoCoeur D Alene$2K
- Donald EnglesCoeur D Alene$2K
- Dennis CookeCoeur D Alene$423
- Joseph WalshBoise$115K
- Kara DenbyBoise$18K
- Jeffrey HeslopBoise$17K
- Kendra CoonseBoise$17K
- Patrick ColemanBoise$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.